Revolutionizing Targeted Therapy With EGFR Exon 20 and the Early-Stage NSCLC Setting

, ,
Thoracic Night Live | <b>Reflections on the Pivotal Lung Cancer Data of 2021</b>

Josh Sabari, MD; Nicholas C. Rohs, MD; and Balazs Halmos, MD, discuss the updates with targeted therapy as it relates to the early-stage setting of non–small cell lung cancer as well as those who harbor EGFR exon 20 insertion mutations.

Josh Sabari, MD; Nicholas C. Rohs, MD; and Balazs Halmos, MD, discuss the updates with targeted therapy as it relates to the early-stage setting of non–small cell lung cancer as well as those who harbor EGFR exon 20 insertion mutations.

Funding from Daiichi Sankyo/Content Independently Developed by OncLive